Sociedad Americana de Hirudoterapia

Ministry of Food and Drug Safety

MFDS · South Korea · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Traditional medicinenational regulator

South Korea's drug-safety regulator (formerly KFDA) — leech therapy practised within the Korean Medicine (한의학 / Hanui) tradition; Hirudo medicinalis listed in the Korean Pharmacopoeia.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
South Korea
Leech status
traditional medicine
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Pharmaceutical Affairs Act (약사법)
  • Medical Service Act (의료법) — defines parallel MD / KMD scope
  • Korean Pharmacopoeia, 11th ed., monograph 거머리 (geo-meo-ri)

Prescriber Requirements

  • Korean Medicine Doctor (KMD / 한의사) is the principal prescriber within Hanui system
  • Biomedical physician (MD / 의사) can also prescribe; dual licensing rare
  • Allied health (nurses) under physician's order in hospital settings

Supply Chain & GMP

KMD pharmacies (한약방) traditionally stock dried leech preparations; live-leech supply chain is limited to specialised tertiary hospitals (Seoul National University Hospital, Asan Medical Centre).

Import/Export Rules

Imports require MFDS permission and Animal and Plant Quarantine Agency (APQA) clearance. CITES paperwork for Hirudo spp.

Reimbursement Context

National Health Insurance Service (NHIS / 국민건강보험공단) covers Hanui treatments selectively — hirudotherapy reimbursement depends on diagnostic code and provider type; reconstructive-surgery indications generally covered when delivered by MD.

ASH Editorial Notes

MFDS was renamed from KFDA in 2013; both terms appear in older literature. Korea operates parallel biomedical (MD) and Korean Medicine (KMD) systems — both have leech-therapy scope.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.